PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

Journal of Virology
Emilia FalkowskaDennis R Burton

Abstract

Recently, several broadly neutralizing monoclonal antibodies (bnMAbs) directed to the CD4-binding site (CD4bs) of gp120 have been isolated from HIV-1-positive donors. These include VRC01, 3BNC117, and NIH45-46, all of which are capable of neutralizing about 90% of circulating HIV-1 isolates and all of which induce conformational changes in the HIV-1 gp120 monomer similar to those induced by the CD4 receptor. In this study, we characterize PGV04 (also known as VRC-PG04), a MAb with potency and breadth that rivals those of the prototypic VRC01 and 3BNC117. When screened on a large panel of viruses, the neutralizing profile of PGV04 was distinct from those of CD4, b12, and VRC01. Furthermore, the ability of PGV04 to neutralize pseudovirus containing single alanine substitutions exhibited a pattern distinct from those of the other CD4bs MAbs. In particular, substitutions D279A, I420A, and I423A were found to abrogate PGV04 neutralization. In contrast to VRC01, PGV04 did not enhance the binding of 17b or X5 to their epitopes (the CD4-induced [CD4i] site) in the coreceptor region on the gp120 monomer. Furthermore, in contrast to CD4, none of the anti-CD4bs MAbs induced the expression of the 17b epitope on cell surface-expressed cleav...Continue Reading

Associated Clinical Trials

Mar 16, 2018·John O. Prior

References

Oct 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·C F BarbasE Norrby
Apr 11, 2001·Advances in Immunology·P W Parren, D R Burton
Aug 20, 2002·The Journal of General Virology·P J Klasse, Q J Sattentau
Mar 20, 2003·Proceedings of the National Academy of Sciences of the United States of America·Douglas D RichmanChristos J Petropoulos
Feb 26, 2005·Journal of Virology·Xinzhen YangJoseph Sodroski
Aug 19, 2011·Nature·Laura M WalkerPascal Poignard

❮ Previous
Next ❯

Citations

Jun 30, 2000·Biochemical and Biophysical Research Communications·S TakahashiN Hayashi
Feb 13, 2013·The Journal of Experimental Medicine·Laura E McCoy, Robin A Weiss
Jul 5, 2013·Journal of Virology·Reza KhayatAndrew B Ward
Jan 30, 2014·Viruses·Lili Yang, Pin Wang
Jan 22, 2013·Annual Review of Immunology·Davide Corti, Antonio Lanzavecchia
Feb 4, 2016·Retrovirology·Stefanie A KrummKatie J Doores
Sep 29, 2015·The FEBS Journal·Katie J Doores
Dec 27, 2013·Science China. Life Sciences·Dongxing GuoLinqi Zhang
Mar 13, 2015·The Journal of General Virology·Hanna DrejaÁine McKnight
Aug 25, 2015·Journal of Medicinal Chemistry·Francesca CurreliAsim K Debnath
Jun 6, 2015·Nucleic Acids Research·Hyejin YoonKarina Yusim
Sep 18, 2012·Trends in Microbiology·Mattia BonsignoriM Anthony Moody
Oct 23, 2012·Cell Host & Microbe·Dennis R BurtonRichard Wyatt
Apr 23, 2016·Scientific Reports·Bryan BrineyDennis R Burton
Oct 22, 2013·Vaccine·Torben SchiffnerChristopher J A Duncan
Dec 12, 2012·Virology·Marit J van Gils, Rogier W Sanders
May 12, 2016·Annual Review of Immunology·Dennis R Burton, Lars Hangartner
Jan 31, 2017·Immunological Reviews·Laura E McCoy, Dennis R Burton
Jan 12, 2017·Expert Opinion on Therapeutic Patents·Wen LiShibo Jiang
Apr 24, 2014·Therapeutic Advances in Vaccines·Rajesh Ringe, Jayanta Bhattacharya
Jan 31, 2018·Nature Reviews. Immunology·Laura M Walker, Dennis R Burton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.